![]() |
|
|
Preclinical Safety, Novartis Pharma Ltd. (A.E.M.V., M.C.S., R.M.J.,
V.P.); and
Department of Pharmacology and Toxicology, University of
Arizona (R.L.F., K.B.)
Lung biotransformation of the immunosuppressants, cyclosporin A
(CSA), the hydroxyethyl derivative SDZ IMM 125 (IMM), and the
methylcarbonate derivative SDZ SCP 764 (SCP), was demonstrated in
slices from human and rat. The major biotransformation pathway for CSA
and IMM (0.1-10 µM) was hydroxylation at amino acid 1 to form AM1 or
IMM1, while for SCP it was an esterase cleavage of the methylcarbonate
group to form AM1 in both species. The initial rate (0-1 hr) of human
total metabolite formation increased proportionally with substrate
concentration. AM1 formation was five times greater from SCP, an
esterase pathway, than CSA, an oxidative pathway which was inhibited
(50%) by ketoconazole. At 24 hr human lung CSA metabolite formation
was greater than IMM (3-fold) or SCP (2-fold), whereas rat lung and
liver and human bronchial epithelial cell SCP metabolite formation
generally exceeded CSA or IMM metabolism.
CSA biotransformation is expected to occur throughout the human lung as
demonstrated by the similar metabolite profile and extent of metabolism
by slices derived from five different regions. The scaling of slice
total metabolism to organ metabolism revealed that initially lung CSA
metabolite formation would be equal to liver but with time liver
metabolism would exceed lung for human and rat.
This study has demonstrated that human and rat lung are metabolically
active, exhibiting oxidative and esterase pathways toward cyclosporin
derivatives. The lung will play an important role in this metabolism,
particularly when administered via inhalation; however, the
liver will also be a major organ involved in the total clearance of
these compounds.